JEAN-PAUL RENAUD, PhD, is cofounder and President & Chief Scientific Officer at Urania Therapeutics (formerly RiboStruct), which focuses on rational drug design targeting the human ribosome. Previously, he was cofounder and Chief Scientific Officer at NovAliX and CNRS Research Director in the Structural Biology and Genomics Department at the Institute of Genetics and Molecular and Cellular Biology. Dr Renaud has over 30 years of research experience, along with 48 articles, 4 book chapters and 3 patents to his credit. He also initiated and is the Chairman and Scientific Organizer of the NovAliX Conferences "Biophysics in Drug Discovery".

"The book ... is a surprisingly comprehensive, monumental collection of chapters by a number of researchers in the field of drug discovery. ... [Editor Jean-Paul] Renaud was able to see the broad crucial aspects of the field and therefore able to invite excellent scientists to coauthor this book and cover so many aspects and in so much depth." -- Crystallography Reviews, March 2022

• List of ContributorsPrefaceChapter 01: The Evolving Role of Structural Biology in Drug DiscoveryChapter 02: A Structural View on Druggability: Experimental and Computational ApproachesChapter 03: Structural Chemogenomics: Profiling Protein–Ligand Interactions in Polypharmacological SpaceChapter 04: Fragment-Based Ligand DiscoveryChapter 05: Combining Structural, Thermodynamic and Kinetic Information to Drive Hit-to-Lead ProgressionChapter 06: Allostery as Structure-Encoded Collective Dynamics: Significance in Drug DesignChapter 07: Biophysical Assessment of Target Protein Quality in Structure-Based Drug discoveryChapter 08: An Industrial Perspective on Protein-Ligand Complex CrystallizationChapter 09: Membrane Protein CrystallizationChapter 10: High-throughput Macromolecular Crystallography in Drug Discovery: Evolving in the Midst of RevolutionsChapter 11: Assessment of Crystallographic Structure Quality and Protein – Ligand Complex Structure ValidationChapter 12: Complementary Information from Neutron Crystallography StudiesChapter 13: Determination of Protein Structure and Dynamics by NMR: State of the Art and Application to the Characterization of BiotherapeuticsChapter 14: NMR Studies of Protein – Small Molecule Interactions for Drug DiscoveryChapter 15: Computational Structural Biology for Drug Discovery: Power and LimitationsChapter 16: The Role of Structural Biology in Kinase Inhibitors Drug Discovery SuccessChapter 17: Serine Proteinases from the Blood Coagulation CascadeChapter 18: Epigenetic Proteins as Emerging Drug TargetsChapter 19: Impact of Recently Determined Crystallographic Structures of GPCRs on Drug DiscoveryChapter 20: Targeting Protein–Protein Interactions PerspectiveChapter 21: Mass Spectrometry-Based Strategies for Therapeutic Antibodies Extensive Characterization and Optimization (OptimAbs)Chapter 22: Integrating Evolution of Drug Resistance into Drug Discovery: Lessons from the Viral Proteases of HIV-1 and HCVChapter 23: A Comprehensive Review on Mycobacterium Tuberculosis Targets and Drug Development from a Structural PerspectiveChapter 24: Using Crystal Structures of Drug-Metabolizing Enzymes in Mechanism-Based Modeling for Drug DesignChapter 25: Intrinsically Disordered Proteins (IDPs): Targets for the Future?Chapter 26: Cryo-electron Microscopy as a Tool for Drug Discovery in the Context of Integrative Structural BiologyChapter 27: Application of Hard-X-ray Free-electron Lasers for Static and Dynamic Processes in Structural Biology

JEAN-PAUL RENAUD, PhD, is cofounder and President & Chief Scientific Officer at Urania Therapeutics (formerly RiboStruct), which focuses on rational drug design targeting the human ribosome. Previously, he was cofounder and Chief Scientific Officer at NovAliX and CNRS Research Director in the Structural Biology and Genomics Department at the Institute of Genetics and Molecular and Cellular Biology. Dr Renaud has over 30 years of research experience, along with 48 articles, 4 book chapters and 3 patents to his credit. He also initiated and is the Chairman and Scientific Organizer of the NovAliX Conferences "Biophysics in Drug Discovery".

"The book ... is a surprisingly comprehensive, monumental collection of chapters by a number of researchers in the field of drug discovery. ... [Editor Jean-Paul] Renaud was able to see the broad crucial aspects of the field and therefore able to invite excellent scientists to coauthor this book and cover so many aspects and in so much depth." -- Crystallography Reviews, March 2022

• List of ContributorsPrefaceChapter 01: The Evolving Role of Structural Biology in Drug DiscoveryChapter 02: A Structural View on Druggability: Experimental and Computational ApproachesChapter 03: Structural Chemogenomics: Profiling Protein–Ligand Interactions in Polypharmacological SpaceChapter 04: Fragment-Based Ligand DiscoveryChapter 05: Combining Structural, Thermodynamic and Kinetic Information to Drive Hit-to-Lead ProgressionChapter 06: Allostery as Structure-Encoded Collective Dynamics: Significance in Drug DesignChapter 07: Biophysical Assessment of Target Protein Quality in Structure-Based Drug discoveryChapter 08: An Industrial Perspective on Protein-Ligand Complex CrystallizationChapter 09: Membrane Protein CrystallizationChapter 10: High-throughput Macromolecular Crystallography in Drug Discovery: Evolving in the Midst of RevolutionsChapter 11: Assessment of Crystallographic Structure Quality and Protein – Ligand Complex Structure ValidationChapter 12: Complementary Information from Neutron Crystallography StudiesChapter 13: Determination of Protein Structure and Dynamics by NMR: State of the Art and Application to the Characterization of BiotherapeuticsChapter 14: NMR Studies of Protein – Small Molecule Interactions for Drug DiscoveryChapter 15: Computational Structural Biology for Drug Discovery: Power and LimitationsChapter 16: The Role of Structural Biology in Kinase Inhibitors Drug Discovery SuccessChapter 17: Serine Proteinases from the Blood Coagulation CascadeChapter 18: Epigenetic Proteins as Emerging Drug TargetsChapter 19: Impact of Recently Determined Crystallographic Structures of GPCRs on Drug DiscoveryChapter 20: Targeting Protein–Protein Interactions PerspectiveChapter 21: Mass Spectrometry-Based Strategies for Therapeutic Antibodies Extensive Characterization and Optimization (OptimAbs)Chapter 22: Integrating Evolution of Drug Resistance into Drug Discovery: Lessons from the Viral Proteases of HIV-1 and HCVChapter 23: A Comprehensive Review on Mycobacterium Tuberculosis Targets and Drug Development from a Structural PerspectiveChapter 24: Using Crystal Structures of Drug-Metabolizing Enzymes in Mechanism-Based Modeling for Drug DesignChapter 25: Intrinsically Disordered Proteins (IDPs): Targets for the Future?Chapter 26: Cryo-electron Microscopy as a Tool for Drug Discovery in the Context of Integrative Structural BiologyChapter 27: Application of Hard-X-ray Free-electron Lasers for Static and Dynamic Processes in Structural Biology